Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2018 / Article

Research Article | Open Access

Volume 2018 |Article ID 7415975 | https://doi.org/10.1155/2018/7415975

Jun Miyoshi, Kentaro Nobutani, Mark W. Musch, Daina L. Ringus, Nathaniel A. Hubert, Masahiro Yamamoto, Yoshio Kase, Mitsue Nishiyama, Eugene B. Chang, "Time-, Sex-, and Dose-Dependent Alterations of the Gut Microbiota by Consumption of Dietary Daikenchuto (TU-100)", Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 7415975, 18 pages, 2018. https://doi.org/10.1155/2018/7415975

Time-, Sex-, and Dose-Dependent Alterations of the Gut Microbiota by Consumption of Dietary Daikenchuto (TU-100)

Academic Editor: Vincenzo De Feo
Received08 Dec 2017
Accepted15 Jan 2018
Published22 Feb 2018


Medications or dietary components can affect both the host and the host’s gut microbiota. Changes in the microbiota may influence medication efficacy and interactions. Daikenchuto (TU-100), a herbal medication, comprised of ginger, ginseng, and Japanese pepper, is widely used in Japanese traditional Kampo medicine for intestinal motility and postoperative paralytic ileus. We previously showed in mice that consumption of TU-100 for 4 weeks changed the gut microbiota and increased bioavailability of bacterial ginsenoside metabolites. Since TU-100 is prescribed in humans for months to years, we examined the time- and sex-dependent effects of TU-100 on mouse gut microbiota. Oral administration of 1.5% TU-100 for 24 weeks caused more pronounced changes in gut microbiota in female than in male mice. Changes in both sexes largely reverted to baseline upon TU-100 withdrawal. Effects were time and dose dependent. The microbial profiles reverted to baseline within 4 weeks after withdrawal of 0.75% TU-100 but were sustained after withdrawal of 3% TU-100. In summary, dietary TU-100 changed mouse microbiota in a time-, sex-, and dose-dependent manner. These findings may be taken into consideration when determining optimizing dose for conditions of human health and disease with the consideration of differences in composition and response of the human intestinal microbiota.

1. Introduction

The gut microbiota has a systemic effect on human health [1, 2]. Most ingested compounds, be they dietary, taken for therapeutic benefits, or taken for other purposes, influence the microbiota and conversely the microbiota can also metabolize many orally ingested substances. Thus bacterial enzymes, involved in bacterial metabolism, can also serve to inactivate or activate drugs or herbal medications ingested by the host. Examples of this include the bacterial cytochrome encoding operon of Eggerthella lenta that metabolizes digoxin [3], bacterial glucuronidases that are responsible for the reactivation of the phase II product of the chemotherapeutic drug irinotecan [4], and bacterial glycosidases, and glucosidases that remove sugars, altering intestinal absorption and activity of ginseng dammarane saponins, including ginsenoside Rb1 [5]. Therefore it is important that the bidirectional interactions between medications and intestinal microbiota are considered when assessing drug pharmacokinetics and clinical efficacy [6, 7]. The ability of compounds in TU-100 to alter the microbiota may be due to the presentation of substrates, providing a survival benefit for these bacteria as they may metabolize. However, we cannot exclude the possibility that some compounds in TU-100 inhibit the growth of some bacteria. Both ginger and ginseng extracts as well as shogaols from sansho pepper have been demonstrated to have antimicrobial action [811] but the predominant intestinal bacteria were not included in these studies. Additionally, these studies were performed in vitro, considerably different from conditions in the intestinal tract.

Daikenchuto (TU-100) is a herbal medication used under the aegis of the traditional Kampo therapeutic system in Japan. Kampo has been used for over a thousand years and TU-100 is widely used in Japan to improve gastrointestinal (GI) motility, especially in the lower GI tract, including prevention of postoperative paralytic ileus. TU-100 is an aqueous extract from a mixture of 50% ginger (Zingiber official), 20% Japanese pepper (Zanthoxylum piperitum), and 30% ginseng (Panax ginseng), prepared according to an established formulation [12]. Several clinical studies including multicenter randomized clinical trials have been performed to demonstrate the efficacy of TU-100 and have shown that the administration of TU-100 improves postoperative bowel function [1317].

Although it was approved in 1986 by the Japanese government as a pharmaceutical compound and various mechanisms to explain the effect of TU-100 on improving GI tract motility and blood flow have been proposed [1824], the mechanisms underlying TU-100’s actions are not completely understood. A variety of compounds in TU-100 may lead to complementary and synergetic effects. Ginseng contains many complex carbohydrates and dammarane saponin ginsenosides. Some of these are metabolized and converted to bioactive metabolites by gut microbiota, which makes them more rapidly absorbable. We published that, in mice, dietary administration of TU-100 for 4 weeks altered gut microbiota and increased the ability of the microbiota to convert a major ginsenoside (Rb1) to bioactive compound K [25]. Gingerols and shogaols in ginger are rapidly absorbed in the small intestine and are involved in the enterohepatic circulation via metabolism by the liver, intestine, and gut microbiota [26]. It is well known that gut microbiota plays a role in many GI tract functions of the host including motility [27, 28] and xenobiotic metabolism [29, 30]. Also noteworthy is that sex-specific differences have been reported both with respect to the gut microbiota [31, 32] and also with respect to drug metabolism [33]. We recently reported that long-term consumption of TU-100 affects murine hepatic and intestinal drug metabolizing enzymes [34]. Collectively these findings suggest that the gut microbiota can mediate some of the actions of TU-100 and that more information is needed to understand how greater efficacy and dosing of TU-100 can be achieved.

Since TU-100 can be prescribed long term in clinical settings, to understand its mechanisms of action, it is important to delineate TU-100’s effects in terms of long-term exposure, dose dependency, sex specificity, and reversibility of the effects after cessation of TU-100 exposure in an in vivo model. Therefore, we undertook a long-term, 24-week study, to investigate the chronological change of the gut microbiota in the presence and absence of TU-100 administration, its dose dependence on TU-100, and its reversibility after withdrawal of TU-100 in female and male mice. We believe that this is the first comprehensive study to examine the effect of a herbal medication on the gut microbiota.

2. Materials and Methods

2.1. Animals

C57Bl/6J mice were bred in-house at the University of Chicago Animal Care Facilities (Institutional Animal Care and Use Committee Protocol 71084). Five breeding pairs were set up when mice were 7–9 weeks old and called the F0 generation. Their progeny were termed the F1 generation and were used to set up 25 breeding pairs, with care being taken to avoid using littermates for any breeding pair. For the present study, mice of the F2 generation were used. The F2 generation pups were weaned at 21 days after birth and ear tagged for identification. Fresh bedding is provided every 14 days in our animal facility. Between weaning and the start of the experiments (see below), to decrease cage-cage variability, a mixed bedding protocol was implemented. Thus, 3-4 days and also at 8–10 days after fresh bedding was provided, the mouse bedding was removed and mixed. The bedding from all cages of females and male animals was mixed together and the mixed bedding was distributed back to all cages. Mice were maintained on a 12-hour light 12-hour dark cycle, with light initiated at 6 AM.

2.2. Diet and Drug Treatment

Mice were fed Teklad Global 18% Protein Rodent Diet (2018) (Envigo, Madison, WI, USA) until one week before the start of experiments and then switched to the defined, AIN-76A Purified Diet (CA. 170481) (The American Institute of Nutrition, 1977) (Envigo) for one week. TU-100 was obtained as a powder from Tsumura & Co. (Ami, Ibaraki, Japan). TU-100 was included at 0.75, 1.5, or 3% wt/wt in AIN76A (Institutional Animal Care and Use Committee protocol 72101). The dosage of TU-100 for murine experiments was based on previous reports that aimed to achieve blood concentrations of major TU-100 compounds, similar to that reported in human data [2426, 35, 36].

2.3. Study Designs

Forty-eight female and 48 male mice were used for the first experiment and were 7–12 weeks old at the start of the experimental protocol, labeled as “week 0.” Mice were assigned to 3 groups (groups 1–3) and each group contained 16 female and 16 male mice. Mice in group 1 and group 2 were fed AIN-76A and 1.5% TU-100 for 24 weeks (weeks 0–24), respectively. Group 3 was fed 1.5% TU-100 for 12 weeks (weeks 0–12) and then returned to AIN-76A for another 12 weeks (weeks 12–24). Half of the mice in each group were sacrificed at week 12 and the remaining mice at week 24 (Figure 1(a)). In the second experiment, to study dose-dependent effects, 45 male mice were used and mice were 6–9 weeks old at week 0. The mice were stratified into 5 groups (groups 1–5). Group 1 (5 mice) were fed AIN-76A for 24 weeks (weeks 0–24). Group 2 and group 4 (10 mice in each group) were fed 0.75% and 3.0% TU-100 for 12 weeks (weeks 0–12) and then returned to AIN-76A for another 12 weeks (weeks 12–24), respectively. Group 3 and group 5 (10 mice in each group) were fed 0.75% and 3.0% TU-100 for 24 weeks (weeks 0–24), respectively. Half of the mice in groups 2–5 were sacrificed for tissue samples at week 12 and all mice in group 1 and the other half in groups 2–5 were harvested at week 24 (Figure 1(b)).

2.4. Fecal Samples

Fecal pellets were harvested from the mice every 4 weeks from week 0 through week 24 (Figure 1). The stool was always taken at 6 AM as mouse fecal microbiota changes in a circadian manner [37].

2.5. DNA Extraction and 16S rRNA Gene Sequencing Analysis

DNA was extracted from stool pellets by standard, published protocols [38]. Sequences were obtained at the Next Generation Sequencing Core in the Biosciences Division at Argonne National Laboratory with standard protocols (http://www.earthmicrobiome.org/protocols-and-standards/16s/) using MiSeq (Illumina, San Diego, CA, USA) for sequencing. DNA sequences were analyzed by Quantitative Insights into Microbial Ecology (QIIME) version 1.9.1 [39]. Operational taxonomic units (OTUs) were picked up at 97% sequence identity using the GreenGenes Database (http://greengenes.secondgenome.com/).

2.6. Statistical Analysis

Mann–Whitney U test was performed with GraphPad Prism (GraphPad Software, La Jolla, CA, USA). U tests were employed to examine the changes of the proportions of phyla and genera after TU-100 administration. Kruskal-Wallis test was performed on QIIME generated bacterial abundance percentages to compare the abundance of each OTU between groups. values less than 0.05 were considered statistically significant.

3. Results and Discussion

3.1. Comparison of Fecal Microbiota between Sexes before Administration of TU-100

Analysis of fecal microbiota was performed before switching mice to a defined diet to determine the variability of the starting population. 16S rRNA genes were sequenced and principal coordinate analysis (PCoA) plots generated by QIIME from MiSeq data for 48 female and 48 male samples. Since 6 samples from female mice gave less than 5000 sequences, these samples were excluded. The PCoA plots showed the similar distribution between sexes in both unweighted and weighted UniFrac distances (Figure 2). Unweighted UniFrac distances describe the presence or absence of OTUs in samples while weighted UniFrac distances describe the distribution of proportions of OTUs in samples.

3.2. Difference of Fecal Microbiota with Different Administration Pattern of TU-100

Mice were placed into 3 groups (groups 1–3) in each sex of littermates. As shown in Figure 1(a), mice in group 1 and group 2 were fed AIN76-A and 1.5% TU-100 for 24 weeks (weeks 0–24), respectively. Mice in group 3 were fed 1.5% TU-100 for 12 weeks (weeks 0–12) and then switched to AIN-76A for another 12 weeks (weeks 12–24). In PCoA plots at week 0, the microbiota among mice in each group in each sex appeared to be randomly distributed (Figures 3(a) and 3(b)) before the start of TU-100 administration. After 12 weeks, data for mice in group 2 and group 3 (fed dietary TU-100) clustered together and separately from group 1 without TU-100. Clustering of TU-100 fed mice was observed for both male and female mice in unweighted UniFrac distances. However, differences were not observed in weighted UniFrac distances (Figures 3(c) and 3(d)). These findings demonstrate that dietary TU-100 for 12 weeks changes the bacterial lineages in fecal samples of both sexes; however, the proportion of bacterial lineages was not dramatically changed. At 24 weeks, the plots of group 3 appeared to be separated from the plots of not only group 1 but also group 2 and to be plotted between groups 1 and 2 in both female and male samples in PCoA of unweighted UniFrac distances (Figures 3(e) and 3(f)). This result demonstrated the reversibility of the fecal microbiota at 12 weeks after withdrawal of 12-week intake of 1.5% TU-100 in both sexes. In addition, PCoAs of both unweighted and weighted UniFrac distances indicated that 24-week 1.5% TU-100 consumption changed the composition of the fecal microbiota.

3.3. Chronological Change of Fecal Microbiota with TU-100

To determine how quickly the microbiota changes after addition to the diet and how quickly the changes are reversible, samples were analyzed from fecal DNA at weeks 0, 4, 8, 12, 16, 20, and 24 and the data are shown in Figure 4. In group 1 that never received dietary TU-100, changes in microbiota composition mostly likely reflect the effects of aging. Thus, in interpreting changes with and without TU-100, these data should be viewed in the context of changes that occur with aging. For group 2 which received dietary TU-100 for the entire 24 weeks, changes were nearly complete by week 4 and showed some variation after this point. For group 3, they received dietary TU-100 for weeks 0–12 and then diet without TU-100 for weeks 12–24; as for group 2, changes with TU-100 were nearly complete within 4–8 weeks. Upon removal of TU-100 at week 12, a near-complete reversal was observed at week 16. These chronological changes were more apparent in PCoA of unweighted UniFrac distances of female samples (Figure 4(a)) than male samples (Figure 4(b)). PC1 and PC2 axes are shown for PCoA plots in each panel.

3.4. Alteration of Bacterial Phyla and Genera with TU-100 Administration

16S rRNA sequences were next analyzed by QIIME for taxonomy assignment. We analyzed the composition of phyla in each group at weeks 0, 12, and 24 of female and male samples (Figure 5). Phyla with more than 1.0% of the population in any group at week 24 are listed in Table 1. In the samples from female mice, Bacteroidetes was increased and Proteobacteria was decreased significantly in the comparison of group 1 and group 2. On the other hand, in males, these phyla did not show significant changes. In male samples, however, the phylum Actinobacteria showed a significant increase even though the percentage of the population was still low. Next, we determined the representation of various genera in the same samples. Table 2 shows genera with more than 1.0% of the population in any group that are significantly different between group 1 and group 2 at week 24. In female samples, the genus Bacteroides, one of the family Rikenellaceae, one of the family S24-7, Turicibacter, and one of the family Clostridiaceae increased with TU-100 administration for 24 weeks. In contrast, over the same treatment, one genus of the order Clostridiales and one genus of the family Desulfovibrionaceae decreased significantly. On the other hand, in male samples, one genus of the family Coriobacteriaceae and the genus Allobaculum increased and the genera Turicibacter and Ruminococcus decreased significantly. Furthermore, we examined the change of specific OTUs and the top 20 OTUs that demonstrated significant increases or decreases are shown in Supplementary Table 1 (listed in order of P value). These results showed that 24-week intake of 1.5% TU-100 altered the fecal microbiota in both sexes but the specific changes at the level of phylum, genus, and OTU were different between sexes.

PhylumGroup 1Group 2Group 3 value
(%)(%)(%)(group 1 versus group 2)

Female samples
Bacteroidetes28.95 ± 6.6649.13 ± 10.1342.02 ± 14.770.0012
Deferribacteres3.30 ± 1.553.08 ± 5.940.67 ± 0.68ns
Firmicutes46.23 ± 6.9137.37 ± 10.4945.78 ± 14.46ns
Proteobacteria20.13 ± 3.678.89 ± 3.0210.64 ± 2.510.0003

Male samples
Actinobacteria0.15 ± 0.051.74 ± 1.401.46 ± 2.330.0006
Bacteroidetes40.39 ± 7.8936.53 ± 11.1538.03 ± 9.11ns
Deferribacteres2.23 ± 2.873.43 ± 4.271.62 ± 1.75ns
Firmicutes40.99 ± 10.4441.92 ± 3.6439.95 ± 7.48ns
Proteobacteria14.77 ± 6.1914.97 ± 9.1017.73 ± 8.29ns

–Whitney U test.
(a) Female samples

Genus levelGroup 1Group 2Group 3 value
(%)(%)(%)(group 1 versus group 2)

k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Bacteroidaceae;g__Bacteroides0.85 ± 0.433.53 ± 1.332.45 ± 1.710.0012
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Rikenellaceae;g__1.46 ± 0.894.66 ± 1.871.44 ± 1.060.0012
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__S24-7;g__14.12 ± 2.5124.93 ± 5.9320.13 ± 7.240.0093
k__Bacteria;p__Firmicutes;c__Bacilli;o__Turicibacterales;f__Turicibacteraceae;g__Turicibacter0.16 ± 0.291.50 ± 1.370.92 ± 1.240.0022
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__;g__23.34 ± 5.0914.45 ± 4.4621.38 ± 13.400.0059
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Clostridiaceae;g__0.18 ± 0.071.13 ± 0.640.62 ± 0.470.0003
k__Bacteria;p__Proteobacteria;c__Deltaproteobacteria;o__Desulfovibrionales;f__Desulfovibrionaceae;g__17.05 ± 4.757.35 ± 2.698.85 ± 2.190.0003

–Whitney U test.
(b) Male samples

Genus levelGroup 1Group 2Group 3 value
(%)(%)(%)(group 1 versus group 2)

k__Bacteria;p__Actinobacteria;c__Coriobacteriia;o__Coriobacteriales;f__Coriobacteriaceae;g__0.03 ± 0.021.18 ± 1.250.77 ± 1.480.0006
k__Bacteria;p__Firmicutes;c__Bacilli;o__Turicibacterales;f__Turicibacteraceae;g__Turicibacter1.82 ± 1.880.05 ± 0.080.17 ± 0.170.0200
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;g__[Ruminococcus]1.47 ± 0.450.75 ± 0.190.85 ± 0.300.0006
k__Bacteria;p__Firmicutes;c__Erysipelotrichi;o__Erysipelotrichales;f__Erysipelotrichaceae;g__Allobaculum5.33 ± 3.5217.71 ± 6.2915.44 ± 6.840.0006

–Whitney U test.
3.5. Dose-Dependent Effect of TU-100 on Fecal Microbiota

To determine if the effects of dietary TU-100 are dose dependent, diets were prepared with half and twice the TU-100 (0.75 and 3% wt/wt) as used in experiment 1. For this experiment, 5 groups of male mice were used as shown in Figure 1(b). For practical considerations of the numbers of animals to be handled in each experiment, these studies focused only on male mice. Groups 1, 3, and 5 were fed AIN-76A and 0.75% and 3.0% TU-100 for 24 weeks (weeks 0–24), respectively. Groups 2 and 4 were fed 0.75% and 3.0% TU-100 for 12 weeks (weeks 0–12) and then switched to AIN-76A for another 12 weeks (weeks 12–24), respectively. The fecal microbiotas in each group appeared to be randomly distributed in PCoA plots at week 0 (Figure 6(a)). At week 12, the plots of group 1 (AIN76-A), groups 2 and 3 (0.75% TU-100), and groups 4 and 5 (3.0% TU-100) appeared to be clustered, respectively, in PCoAs of unweighted UniFrac distances while the clustering of the plots of groups 2 and 3 was less apparent than groups 4 and 5 (Figure 6(b)). These results indicated that TU-100 administered for 12 weeks can alter the fecal microbiota at both concentrations of 0.75% and 3.0% while the extent of change to the microbiota caused by each concentration differs. At week 24, the plots of groups 3, 4, and 5 appeared to be clustered and group 2 was separated from group 3 in PCoAs of both unweighted and weighted UniFrac distances. Group 2 also seemed to show the similar distribution to group 1 rather than to group 3 (Figure 6(c)). These findings can be summarized by the following: (a) the administration of 0.75% TU-100 for 24 weeks caused similar changes in fecal microbiota as 3.0% TU-100 for 24 weeks and (b) the fecal microbiota of animals, which had been administered 0.75% TU-100 for 12 weeks and then maintained in the absence of TU-100 for 12 weeks, reverted to a baseline profile, whereas (c) those that had been administered 3.0% TU-100 for 12 weeks and then maintained in the absence of TU-100 for 12 weeks showed no reversibility in profile of the fecal microbiota. Of note the group size for these dose-dependence experiments is smaller (5 versus 7-8 for experiment 1). Statistical analysis of data from smaller group sizes will determine statistical significance only when larger changes are observed in the smaller groups. Smaller changes that might be significant in an experiment with larger group sizes will not be found to be significant in experiments with smaller group sizes.

3.6. Chronological Change of Fecal Microbiota with Different Dose TU-100

We next analyzed the chronological change of fecal microbiota in each group using fecal DNA samples at weeks 0, 4, 8, 12, 16, 20, and 24 (Figure 7). The continuous changes in gut microbiome observed in group 1 (AIN-76A for 24 weeks) are likely related to age-dependent changes in gut microbiota. A diet containing 3.0% TU-100 resulted in a microbiota that had shifted by week 4 (groups 4 and 5). A diet containing 0.75% TU-100 changed the microbiota less than a diet containing 3.0% TU-100 at week 12, while continuous consumption of 0.75% TU-100 for longer than 16 weeks showed changes of microbiota similar to those caused by 3.0% TU-100 (group 3). Withdrawal of 0.75% TU-100, after consumption for 12 weeks, demonstrated that the reversibility of microbiota was complete by week 16 (i.e., 4 weeks after withdrawal of 0.75%, group 2). However there was no reversibility in the microbiota after withdrawal of 3.0% TU-100 (group 4). These findings indicate that (1) TU-100 has a dose-dependent effect, (2) the effect of 0.75% TU-100 on fecal microbiota is reversible, and (3) the administration of 3.0% TU-100 for 12 weeks has a long-lasting influence on the fecal microbiota.

3.7. Alteration of Bacterial Phyla and Genera with Different Dose TU-100 Administration

We examined the gut microbial composition in each group at weeks 0, 12, and 24 (Figure 8). The phyla with more than 1.0% of the population in any group are listed in Table 3. The phylum Actinobacteria decreased significantly in group 3 compared to group 1. Although group 5 did not present any significant difference from group 1, groups 3 and 5 demonstrated the same trend of change at the level of phylum. Table 4 shows the genera with more than 1.0% of the population in any group showing a significant difference between group 1 and group 3 or group 1 and group 5. In the comparison between group 1 and group 3, the genera one of the family Rikenellaceae, Rikenella and Lactococcus increased while one genus of the family Coriobacteriaceae decreased significantly in group 3. On the other hand, group 5 showed the significant increase of one genus of the family Rikenellaceae and AF12 and decrease of one genus of the family Coriobacteriaceae and Ruminococcus, compared to group 1. Of note, between 0.75% and 3.0% TU-100, genera that showed significant changes with one dose of TU-100 also demonstrated the same trend of change with the other dose. We also analyzed the change of OTUs in the comparison between group 1 and group 3 and group 1 and group 5. Supplementary Table 2 shows the top 20 OTUs that increased significantly and all 15 OTUs that decreased significantly in group 3 compared to group 1. The top 20 OTUs that increased and decreased significantly in the comparison between group 1 and group 5 are shown in Supplementary Table 3. These OTUs are ordered by value. These results demonstrated that (1) both 24-week consumption of 0.75% and 3.0% TU-100 changed the fecal microbiota, (2) these changes differed between doses although they elicited a similar trend at the level of phylum and genus, and (3) withdrawal of 3.0% TU-100 after 12-week administration did not show reversibility of microbiota even after a 12-week withdrawal period.

PhylumGroup 1Group 2Group 3Group 4Group 5 value value
(%)(%)(%)(%)(%)(group 1 versus group 3)(group 1 versus group 5)

Actinobacteria1.17 ± 0.640.67 ± 0.570.31 ± 0.130.31 ± 0.290.59 ± 0.530.0317ns
Bacteroidetes41.58 ± 8.4539.99 ± 9.6144.80 ± 6.2633.43 ± 9.7945.84 ± 19.47nsns
Deferribacteres1.17 ± 1.111.97 ± 3.313.67 ± 4.055.01 ± 4.566.15 ± 7.07nsns
Firmicutes42.05 ± 3.1742.67 ± 3.7238.41 ± 10.0039.58 ± 7.3334.20 ± 7.70nsns
Proteobacteria13.33 ± 6.6914.11 ± 5.4011.8 ± 2.0620.87 ± 11.3012.58 ± 8.96nsns

–Whitney U test.

Genus levelGroup 1Group 2Group 3Group 4Group 5 value value
(%)(%)(%)(%)(%)(group 1 versus group 3)(group 1 versus group 5)

k__Bacteria;p__Actinobacteria;c__Coriobacteriia;o__Coriobacteriales;f__Coriobacteriaceae;g__1.03 ± 0.560.60 ± 0.540.08 ± 0.040.21 ± 0.260.06 ± 0.040.01590.0159
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Rikenellaceae;g__1.19 ± 0.410.91 ± 0.725.43 ± 2.703.36 ± 0.803.66 ± 1.950.01590.0317
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Rikenellaceae;g__AF120.79 ± 0.330.74 ± 0.281.41 ± 0.321.77 ± 0.921.34 ± 0.15ns0.0317
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Rikenellaceae;g__Rikenella0.42 ± 0.330.32 ± 0.221.30 ± 0.271.42 ± 0.640.56 ± 0.330.0159ns
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Streptococcaceae;g__Lactococcus0.59 ± 0.260.71 ± 0.551.44 ± 0.381.29 ± 1.310.84 ± 0.700.0159ns
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;g__[Ruminococcus]1.05 ± 0.420.67 ± 0.200.90 ± 0.640.87 ± 0.230.54 ± 0.17ns0.0317

The present study demonstrates the effect of TU-100 administration and withdrawal on fecal microbiota in both female and male mice and the effects of different doses in male mice for 24 weeks. Our study provides insight into determining the clinical efficacy and safety of TU-100 and its influence on the microbiota by examining the following parameters: (1) both female and male animals were studied, (2) chronological changes over a long (24 weeks) observation period, (3) analyses of reversibility of microbiota after cessation of TU-100, and (4) analyses of the dose-dependent effects of TU-100. It is well known that the intestinal microbiota in mice differs from humans. TU-100 may alter the intestinal microbiota by providing substrates for certain bacterial species, increasing their abundance, or some components may provide compounds with antimicrobial actions against certain intestinal bacteria. It is not possible to predict what changes might occur in the human intestinal microbiota from changes in phyla and genera that changed in mice. However, if the bacteria have similar properties in the human and mouse microbiota, changes may occur and remained to be determined.

A general consideration of microbiota studies is to minimize variations in the starting microbiota between groups prior to experimentation, that is, to start with a consistent baseline. It is increasingly recognized that, even within the same facility, and using the same mouse strain, there are room to room and cage to cage differences that influence the microbial profile. For this purpose, in the present study, we adopted a protocol of mixed bedding among all cages in each experiment from weaning until the start of the experiments as described in the Materials and Methods. The plots in each group appeared to be randomly distributed in PCoAs at the start point among each sex and experiment. We attribute this to our methodology of bedding transfers. The mixed bedding protocol is thought to reduce the variability of fecal microbiota among cages safely (Miyoshi et al., manuscript in preparation).

In the present study, the doses of TU-100 were determined to achieve blood concentrations of major TU-100 compounds similar to those in human [2426, 35, 36]. Our first experiment showed the continuous chronological change of fecal microbiota with the administration of 1.5% TU-100 for 24 weeks and the reversibility of fecal microbiota after withdrawal. These results suggest that longer-term consumption of 1.5% TU-100 more effectively alters the composition of gut microbiota compared to shorter treatment periods and that the effect of 1.5% TU-100 on gut microbiota does not persist for a long time after its cessation (Figures 3 and 4). Importantly, the greater effect of TU-100 on female compared to male animals suggests that there are sex differences in response to dietary TU-100. In addition, our second experiment conducted in male animals demonstrated that 0.75% and 3.0% TU-100 lead to similar alterations of fecal microbiotas after 16-week administration, with the changes occurring much faster (near completion in 4 weeks) in the groups fed 3.0% TU-100. A reversibility of changes in the fecal microbiota was observed after withdrawal of 12-week 0.75% TU-100 but not after withdrawal of 12-week 3.0% TU-100. These results show that the higher dose of TU-100 alters the composition of gut microbiota more rapidly and its effects persist over a longer period, compared to a lower dose of TU-100.

Our recent report using the same murine model demonstrated that dietary TU-100 modulates the transcript and protein expression of drug metabolizing enzymes and drug transporters in the liver, small intestine, and colon in a dose- and sex-dependent manners and that in most cases the effects were reversible after cessation of TU-100 treatment [34]. Taken together, our results show an interactive network between consumption of TU-100, alterations of gut microbiota, and changes in host xenobiotic metabolism. This idea is supported by several previous reports that gut microbiota plays an important role in regulating xenobiotic metabolism in the host [30, 4043]. Interventions that can modify these interactions could be used to improve clinical efficacy and safety of TU-100.

Our analysis of the changes of phyla and genera revealed interesting differences between sexes. Bolnick et al. [31] demonstrated that the diet-microbiota association is sex-dependent and dietary TU-100 may affect gut microbiota differently in female and male animals. We speculate that this sex difference occurs by the synergistic effects of the following: (1) the difference in composition of microbiota between sexes at the start of TU-100 administration, (2) a sex-dependent selection of colonized microbes, and (3) a difference in metabolism/bioactive-conversion of TU-100 in the two sexes. The difference of gut microbiota contributes to the difference of host drug metabolism and therapeutic efficacy [44] and our findings seem to underscore the importance of analyzing both female and male animals for investigating the drug effect on gut microbiota. The change of bacterial compositions in male animals with 1.5% TU-100 was different from our previous study using male animals [25], underscoring the challenges that microbiota studies pose. First one is the length of the observation period (the present study was for 24 weeks and the previous study for 4 weeks). Second, although we used C57Bl/6J house-bred mice for both studies, these studies were conducted at different times (the present study was in 2015 and the previous study in 2011) and each study used a different room in our mouse facility, although they were maintained under the same facility regulations. Several reports have shown that differences in gut microbiota between research facilities can influence the outcome of experiments even in the same strain of mice. For example, Ivanov et al. showed that there is a difference in gut microbiota between mice from Jackson Laboratory and Taconic Farms, leading to a difference in Th17 population in lamina propria of the small intestine [45]. In addition, Moon et al. [46] observed different IgA phenotypes between two facilities in the same strain of mice and found that phenotypes can be vertically transmitted through the microbiota. These findings highlight the importance of using cohorts with normalized starting microbiota. As this was not done for our previous cohorts, differences in starting microbiota likely influenced the results. The present study, however, began with large starting cohort that was normalized for starting microbiota and housed in one specific room. While this made the experiment labor-intensive and technically challenging, reproducibility was enhanced that was conducive to meaningful comparisons.

We therefore addressed the question of whether there was variability between our experiments 1 and 2. In experiment 2, the genus of the family of Rikenellaceae increased with both 0.75% and 3.0% TU-100 and the genus of the family Coriobacteriaceae decreased with both 0.75% and 3.0% TU-100, and some genera showing significant change with one dose of TU-100 presented the same trend of change with the other dose. Taken together, the alterations of the microbiota after 0.75% and 3.0% TU-100 administration for 24 weeks appeared to be similar. On the other hand, the changes of genera with 1.5% TU-100 seemed different from the changes with 0.75% and 3.0% TU-100 (Tables 2 and 4). We speculate that these differences in alterations of genera between 1.5% and 0.75/3.0% TU-100 are due subtle differences in starting microbiota. The plots of experiments 1 and 2 at week 0 clustered separately in both unweighted and weighted UniFrac distances (Supplementary Figure 1(A)) and the bacterial phyla compositions of each experiment differed (Supplementary Figure 1(B)). This difference could be because the experiments were conducted separately, although all animals for the two experiments were derived from the same 25 breeding pairs and housed in the same room. Given our finding of the aging effect on gut microbiota, it is possible that the microbiota to which litters are exposed by their sires and dams can be different along with the aging of breeding pairs.

We also examined the change of 16S rRNA OTUs, recognizing that these data cannot resolve beyond a genus level and provide no functional information. Among females and males in experiment 1, many OTUs that belong to the family of Desulfovibrionaceae decreased and many that belong to the genus Allobaculum increased. The family of Desulfovibrionaceae includes the genera Desulfovibrio, Desulfobaculum, Desulfocurvus, Bilophila, and Lawsonia[47] and the genus Desulfovibrio is listed in our Supplementary Table 1. The genera Desulfovibrio, Desulfobaculum, and Desulfocurvus are regarded as sulfate-reducing bacteria [47]. The genus Allobaculum contains butyrate-producing members (our group, unpublished), and butyrate is the main energy source for colonocytes [48]. More ideal would have been additional studies using metagenomic, metatranscriptomic, and metabolomic data to assess functional profiles of microbial communities. These studies are planned for the future. Another limitation of the present study is the fact that we used the fecal samples to analyze microbiota that are an admixture of luminal microbiota of small intestine and large intestine, where the primary effects of TU-100 on regional GI tract microbiota could therefore not be determined.

4. Conclusions

The administration of dietary TU-100 alters murine fecal microbiota over time for 24 weeks. These changes are time, sex, and dose dependent. At higher doses of TU-100, the changes in gut microbiota are more rapid, pronounced, and sustained. Whether TU-100 changes human intestinal microbiota will determine if similar changes occur.


GI:Gastrointestinal tract
QIIME:Quantitative Insights into Microbial Ecology
OTUs:Operational taxonomic units
PCoA:Principal coordinate analysis.

Additional Points

Accession Numbers. The accession numbers for the mouse sample information and the microbial dataset reported in this paper are BioProject: PRJNA403836 and SRA: SRP117766, respectively.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.


This work was supported by a grant from Tsumura & Co. (EBC), NIH grants Digestive Disease Center grant P30 DK42086 (EBC), NIH RO1 DK097268 (EBC), and support from the GI Research Foundation of Chicago (EBC). The authors thank Mrinalini Rao for her help in editing the manuscript.

Supplementary Materials

Supplementary Figure  1: the difference in male fecal microbiotas at week 0 between experiments 1 and 2. (A) The PCoA plots of unweighted and weighted UniFrac distances were generated for male fecal microbiotas at week 0 in experiments 1 (red squares) and 2 (blue circles). Both PCoA plots showed the different distribution between experiments. (B) The composition of phyla at week 0 of male samples in both experiments is assigned. Supplementary Table  1: the OTUs with significant increase and decrease by 1.5% TU-100 administration for 24 weeks. Supplementary Table  2: the OTUs with significant increase and decrease by 0.75% TU-100 administration for 24 weeks. Supplementary Table  3: the OTUs with significant increase and decrease by 3.0% TU-100 administration for 24 weeks. (Supplementary Materials)


  1. S. Carding, K. Verbeke, D. T. Vipond, B. M. Corfe, and L. J. Owen, “Dysbiosis of the gut microbiota in disease,” Microbial Ecology in Health & Disease, vol. 26, no. 1, 2015. View at: Publisher Site | Google Scholar
  2. A. B. Shreiner, J. Y. Kao, and V. B. Young, “The gut microbiome in health and in disease,” Current Opinion in Gastroenterology, vol. 31, no. 1, pp. 69–75, 2015. View at: Publisher Site | Google Scholar
  3. H. J. Haiser, D. B. Gootenberg, K. Chatman, G. Sirasani, E. P. Balskus, and P. J. Turnbaugh, “Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta,” Science, vol. 341, no. 6143, pp. 295–298, 2013. View at: Publisher Site | Google Scholar
  4. A. M. Stringer, R. J. Gibson, R. M. Logan, J. M. Bowen, A. S. J. Yeoh, and D. M. K. Keefe, “Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhoea model in rats,” Cancer Biology & Therapy, vol. 7, no. 12, pp. 1919–1925, 2008. View at: Publisher Site | Google Scholar
  5. H. Hasegawa, K.-S. Lee, T. Nagaoka et al., “Pharmacokinetics of ginsenoside deglycosylated by intestinal bacteria and its transformation to biologically active fatty acid esters,” Biological & Pharmaceutical Bulletin, vol. 23, no. 3, pp. 298–304, 2000. View at: Publisher Site | Google Scholar
  6. X. Liang, K. Bittinger, L. Xuanwen, D. R. Abernethy, F. D. Bushman, and G. A. Fitzgerald, “Bidirectional interactions between indomethacin and the murine intestinal microbiota,” eLife, vol. 4, Article ID e08973, 2015. View at: Publisher Site | Google Scholar
  7. P. M. Ryan, L. E. E. London, T. C. Bjorndahl et al., “Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E-/- mice,” Microbiome, vol. 5, no. 1, article no. 30, 2017. View at: Publisher Site | Google Scholar
  8. A. H. Rahmani, F. M. Al shabrmi, and S. M. Aly, “Active ingredients of ginger as potential candidates in the prevention and treatment of diseases via modulation of biological activies,” International Journal of Physiology, Pathophysiology and Pharmacology, vol. 6, no. 2, pp. 125–136, 2014. View at: Google Scholar
  9. S. Gupta and S. Ravishankar, “A comparison of the antimicrobial activity of garlic, ginger, carrot, and turmeric pastes against Escherichia coli O157:H7 in laboratory buffer and ground beef,” Foodborne Pathogens and Disease, vol. 2, no. 4, pp. 330–340, 2005. View at: Publisher Site | Google Scholar
  10. K. Kachur and Z. E. Suntres, “The antimicrobial properties of ginseng and ginseng extracts,” Expert Review of Anti-infective Therapy, vol. 14, no. 1, pp. 81–94, 2016. View at: Publisher Site | Google Scholar
  11. P. Xue, Y. Yao, X.-S. Yang, J. Feng, and G.-X. Ren, “Improved antimicrobial effect of ginseng extract by heat transformation,” Journal of Ginseng Research, vol. 41, no. 2, pp. 180–187, 2017. View at: Publisher Site | Google Scholar
  12. T. Kono, M. Shimada, M. Yamamoto et al., “Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: Analysis of daikenchuto,” Frontiers in Pharmacology, vol. 6, article no. 159, 2015. View at: Publisher Site | Google Scholar
  13. M. Nishi, M. Shimada, H. Uchiyama et al., “The beneficial effects of Kampo medicine Dai-ken-chu-to after hepatic resection: a prospective randomized control study,” Hepatogastroenterol, vol. 59, no. 119, pp. 2290–2294, 2012. View at: Google Scholar
  14. K.-I. Okada, M. Kawai, S. Hirono et al., “Perioperative administration of daikenchuto (TJ-100) reduces the postoperative paralytic ileus in patients with pancreaticoduodenectomy,” Hepato-Gastroenterology, vol. 62, no. 138, pp. 466–471, 2015. View at: Publisher Site | Google Scholar
  15. M. Shimada, Y. Morine, H. Nagano et al., “Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001),” International Journal of Clinical Oncology, vol. 20, no. 1, pp. 95–104, 2015. View at: Publisher Site | Google Scholar
  16. K. Yoshikawa, M. Shimada, M. Nishioka et al., “The effects of the Kampo medicine (Japanese herbal medicine) ''Daikenchuto'' on the surgical inflammatory response following laparoscopic colorectal resection,” Surgery Today, vol. 42, no. 7, pp. 646–651, 2012. View at: Publisher Site | Google Scholar
  17. K. Yoshikawa, M. Shimada, G. Wakabayashi et al., “Effect of Daikenchuto, a Traditional Japanese Herbal Medicine, after Total Gastrectomy for Gastric Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Trial,” Journal of the American College of Surgeons, vol. 221, no. 2, pp. 571–578, 2015. View at: Publisher Site | Google Scholar
  18. Y. Kito and H. Suzuki, “Effects of Dai-kenchu-to on spontaneous activity in the mouse small intestine,” Journal of Smooth Muscle Research, vol. 42, no. 6, pp. 189–201, 2006. View at: Publisher Site | Google Scholar
  19. T. Kono, Y. Omiya, Y. Hira et al., “Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous adrenomedullin in Crohn's disease rat model.,” Journal of Gastroenterology, vol. 46, no. 10, pp. 1187–1196, 2011. View at: Publisher Site | Google Scholar
  20. P. Murata, Y. Kase, A. Ishige, H. Sasaki, S. Kurosawa, and T. Nakamura, “The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats,” Life Sciences, vol. 70, no. 17, pp. 2061–2070, 2002. View at: Publisher Site | Google Scholar
  21. K. Satoh, Y. Kase, T. Hayakawa, P. Murata, A. Ishige, and H. Sasaki, “Dai-kenchu-to enhances accelerated small intestinal movement,” Biological & Pharmaceutical Bulletin, vol. 24, no. 10, pp. 1122–1126, 2001. View at: Publisher Site | Google Scholar
  22. Y. Tokita, M. Yamamoto, K. Satoh et al., “Possible involvement of the transient receptor potential vanilloid type 1 channel in postoperative adhesive obstruction and its prevention by a kampo (traditional Japanese) medicine, daikenchuto,” Journal of Pharmacological Sciences, vol. 115, no. 1, pp. 75–83, 2011. View at: Publisher Site | Google Scholar
  23. Y. Tokita, M. Yuzurihara, M. Sakaguchi, K. Satoh, and Y. Kase, “The pharmacological effects of Daikenchuto, a traditional herbal medicine, on delayed gastrointestinal transit in rat postoperative ileus,” Journal of Pharmacological Sciences, vol. 104, no. 4, pp. 303–310, 2007. View at: Publisher Site | Google Scholar
  24. N. Ueno, T. Hasebe, A. Kaneko et al., “TU-100 (Daikenchuto) and ginger ameliorate anti-CD3 antibody induced T cell-mediated murine enteritis: Microbe-independent effects involving Akt and NF-kB suppression,” PLoS ONE, vol. 9, no. 5, Article ID e97456, 2014. View at: Publisher Site | Google Scholar
  25. T. Hasebe, N. Ueno, and M. W. Musch, “Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K,” Pharmacology Research & Perspectives, vol. 4, no. 1, Article ID e00215, 2016. View at: Publisher Site | Google Scholar
  26. J. Watanabe, N. Kaifuchi, H. Kushida et al., “Intestinal, portal, and peripheral profiles of daikenchuto (TU-100)'s active ingredients after oral administration,” Pharmacology Research & Perspectives, vol. 3, no. 5, p. e00165, 2015. View at: Publisher Site | Google Scholar
  27. E. M. M. Quigley, “Microflora modulation of motility,” Journal of Neurogastroenterology and Motility, vol. 17, no. 2, pp. 140–147, 2011. View at: Publisher Site | Google Scholar
  28. J. M. Yano, K. Yu, G. P. Donaldson et al., “Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis,” Cell, vol. 161, no. 2, pp. 264–276, 2015. View at: Publisher Site | Google Scholar
  29. S. P. Claus, S. L. Ellero, B. Berger et al., “Colonization-induced host-gut microbial metabolic interaction,” mBio, vol. 2, no. 2, 2011. View at: Publisher Site | Google Scholar
  30. W. Meinl, S. Sczesny, R. Brigelius-Flohé, M. Blaut, and H. Glatt, “Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in the rat,” Drug Metabolism and Disposition, vol. 37, no. 6, pp. 1179–1186, 2009. View at: Publisher Site | Google Scholar
  31. D. I. Bolnick, L. K. Snowberg, P. E. Hirsch et al., “Individual diet has sex-dependent effects on vertebrate gut microbiota,” Nature Communications, vol. 5, article 4500, 2014. View at: Publisher Site | Google Scholar
  32. J. G. M. Markle, D. N. Frank, S. Mortin-Toth et al., “Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity,” Science, vol. 339, no. 6123, pp. 1084–1088, 2013. View at: Publisher Site | Google Scholar
  33. D. J. Waxman and M. G. Holloway, “Sex differences in the expression of hepatic drug metabolizing enzymes,” Molecular Pharmacology, vol. 76, no. 2, pp. 215–228, 2009. View at: Publisher Site | Google Scholar
  34. K. Nobutani, J. Miyoshi, M. W. Musch et al., “Daikenchuto (TU-100) alters murine hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model: effects of gender and withdrawal,” Pharmacology Research and Perspectives, vol. 5, no. 5, Article ID e00361, 2017. View at: Publisher Site | Google Scholar
  35. A. Kaneko, T. Kono, N. Miura, N. Tsuchiya, and M. Yamamoto, “Preventive effect of TU-100 on a type-2 model of colitis in mice: Possible involvement of enhancing adrenomedullin in intestinal epithelial cells,” Gastroenterology Research and Practice, vol. 2013, Article ID 384057, 8 pages, 2013. View at: Publisher Site | Google Scholar
  36. T. Kono, A. Kaneko, Y. Omiya, K. Ohbuchi, N. Ohno, and M. Yamamoto, “Epithelial transient receptor potential ankyrin 1 (TRPA1)-dependent adrenomedullin upregulates blood flow in rat small intestine,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 304, no. 4, pp. G428–G436, 2013. View at: Publisher Site | Google Scholar
  37. V. Leone, S. M. Gibbons, K. Martinez et al., “Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism,” Cell Host & Microbe, vol. 17, no. 5, pp. 681–689, 2015. View at: Publisher Site | Google Scholar
  38. Y. Wang, J. D. Hoenig, K. J. Malin et al., “16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis,” The ISME Journal, vol. 3, no. 8, pp. 944–954, 2009. View at: Publisher Site | Google Scholar
  39. J. G. Caporaso, J. Kuczynski, J. Stombaugh et al., “QIIME allows analysis of high-throughput community sequencing data,” Nature Methods, vol. 7, no. 5, pp. 335-336, 2010. View at: Publisher Site | Google Scholar
  40. B. Bjorkholm, C. M. Bok, A. Lundin, J. Rafter, M. L. Hibberd, and S. Pettersson, “Intestinal microbiota regulate xenobiotic metabolism in the liver,” PLoS ONE, vol. 4, no. 9, Article ID e6958, 2009. View at: Publisher Site | Google Scholar
  41. T. Kuno, M. Hirayama-Kurogi, S. Ito, and S. Ohtsuki, “Effect of Intestinal Flora on Protein Expression of Drug-Metabolizing Enzymes and Transporters in the Liver and Kidney of Germ-Free and Antibiotics-Treated Mice,” Molecular Pharmaceutics, vol. 13, no. 8, pp. 2691–2701, 2016. View at: Publisher Site | Google Scholar
  42. R. Saad, M. R. Rizkallah, and R. K. Aziz, “Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes,” Gut Pathogens, vol. 4, no. 1, article 16, 2012. View at: Publisher Site | Google Scholar
  43. F. P. Selwyn, J. Y. Cui, and C. D. Klaassen, “Special section on drug metabolism and the microbiome RNA-seq quantification of hepatic drug processing genes in germ-free mice,” Drug Metabolism and Disposition, vol. 43, no. 10, pp. 1572–1580, 2015. View at: Publisher Site | Google Scholar
  44. E. F. Enright, C. G. Gahan, S. A. Joyce, and B. T. Griffin, “The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome,” Yale Journal of Biology and Medicine, vol. 89, no. 3, pp. 375–382, 2016. View at: Google Scholar
  45. I. I. Ivanov, K. Atarashi, N. Manel et al., “Induction of intestinal Th17 cells by segmented filamentous bacteria,” Cell, vol. 139, no. 3, pp. 485–498, 2009. View at: Publisher Site | Google Scholar
  46. C. Moon, M. T. Baldridge, M. A. Wallace, C.-A. D. Burnham, H. W. Virgin, and T. S. Stappenbeck, “Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation,” Nature, vol. 521, no. 7550, pp. 90–93, 2015. View at: Publisher Site | Google Scholar
  47. E. Rosenberg, The prokaryotes : deltaproteobacteria and epsilonproteobacteria, Springer, New York, NY, USA, 4th edition, 2014.
  48. D. R. Donohoe, N. Garge, X. Zhang et al., “The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon,” Cell Metabolism, vol. 13, no. 5, pp. 517–526, 2011. View at: Publisher Site | Google Scholar

Copyright © 2018 Jun Miyoshi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.